We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Sweat-Based On-Site Immunoassay for Monitoring Marijuana Use

By LabMedica International staff writers
Posted on 16 Jan 2020
A novel sweat-based skin test enables on-site testing for tetrahydrocannabinol (THC), the main psychoactive component found in marijuana plants (Cannabis).

This development was made in response to the increase in the number of states legalizing marijuana. More...
This has left law enforcement in a situation where the use and consumption of the drug are legal, but there are no limitations for what is acceptable for driving or operating machinery. The prototype THC detector anticipates the formulation of laws restricting THC consumption by drivers and the need for the police to be able to detect abuse of the substance.

Investigators at University at Albany, State University of New York (USA) had already developed a sweat-based device for measurement of alcohol in the blood. The new device operates in a similar fashion but displays a color change when THC interacts with a specific antibody.

In the new assay system, the THC metabolite and an enzyme-labeled conjugate compete against each other as the antigens for the system. The antibody used in this assay has a greater affinity for the metabolite; so as its concentration increases, the absorbance of the system decreases due to reduced binding of the enzyme-labeled conjugate. Thus, the presence of THC in the sample inhibits the color change generated by the test, and the greater the amount of THC metabolite present in the sweat sample, the less color is produced by the test reagents.

“Currently there is a zero-tolerance policy when it comes to marijuana use and operating machinery,” said senior author Dr Jan Halámek, assistant professor of chemistry at the University at Albany. “While many states are moving to various stages of legalization, the focus is mostly on possession and in-home use. There are no reliable roadside devices being used to test for marijuana-impaired driving. What makes the use of sweat as a biometric unique is that it is non-invasive. No blood needs to be drawn for a sample. Our test can be done instantaneously, on the side of the road, which eliminates any possibility of tampering.”

“While drugs are a new topic for the Halámek lab, it is something we plan to continue diving into,” said Dr. Halámek. “Much of the fundamentals are the same as our previous research in terms of the collection, extraction, and use of sweat as a biometric.”

The THC sweat-based assay was described in the December 3, 2019, online edition of the journal ACS Sensors.

Related Links:
University at Albany, State University of New York


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
HPV Test
Allplex HPV28 Detection
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.